Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Icon Capital AS on the acquisition of M2 Retail Solutions AB and Scandinavian Retail Partner Ltd
Mandate

Vinge advises Icon Capital AS on the acquisition of M2 Retail Solutions AB and Scandinavian Retail Partner Ltd

September 05, 2011

Vinge has advised Icon Capital AS in connection with the acquisition of M2 Retail Solutions AB and Scandinavian Retail Partner Ltd. M2 Retail Solutions AB is a Swedish company which develops and supplies turnkey retail store solutions to global actors and has operations in Halmstad and Copenhagen as well as Hong Kong where the operations are conducted through Scandinavian Retail Partners Ltd.

Vinge's team consisted of partner Fredrik Sonander together with, among others, associates Johanna Björnum Nyström (project manager), Patrik Gargolinski and Anna Siesing. Associate Maria Pajkull advised on the environmental law aspects of the transaction.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026